# Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

> **NCT05288205** · PHASE1,PHASE2 · RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- KRAS P.G12C
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Ductal Carcinoma

## Interventions

- **DRUG:** JAB-21822
- **DRUG:** JAB-3312

## Key facts

- **NCT ID:** NCT05288205
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-14
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288205, "Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05288205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*